Good Biotech Corp. 最新消息News from the Good Biotech Corp. scripting world
http://good-biotech.com
2024-03-19T22:07:36+01:00good-biotech.com logo
http://good-biotech.com
http://good-biotech.com/images/footer_logo.jpgtext/html1970-01-01T00:00:00+01:00http://good-biotech.comgood-biotech.comFerritin LIT Assay Determination for Iron Deficiency
http://good-biotech.com/news/?id=54
<p><img src="/archive/image/20240203%20Ferritin%20LIT%20KIT%20DM.jpg" width="820" height="510" alt="" /></p>text/html1970-01-01T00:00:00+01:00http://good-biotech.comgood-biotech.comAntimalarial IgY(ΔFc)Ab drug for severe&MDR malaria
http://good-biotech.com/news/?id=53
<h6><span style="font-size: medium;"><b><span style="color: rgb(51, 102, 153);" lang="EN-US">The Development of IgY(ΔFc) Antibody to Plasmodium falciparum as a Passive Antibody for Specific Treatment of Severe Malaria Infection, including MDR Malaria</span></b></span><b><span style="font-size:13.0pt;
mso-fareast-font-family:新細明體;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:#336699;mso-font-kerning:0pt" lang="EN-US"><o:p></o:p></span></b></h6>
<p><span style="font-size: small;"><b><span style="color: rgb(0, 102, 0);" lang="EN-US">WHO Urges Increased Implementation of Recommended Tools to Combat Malaria</span></b></span><span style="font-size:12.5pt" lang="EN-US"> <o:p></o:p></span></p>
<p><span style="font-family: Verdana;"><span style="font-weight: normal;" lang="EN-US">In recent World Malaria Day, April 25 2023, the World Health Organization (WHO) is issuing a call for increased implementation of new and existing interventions to save lives from malaria. WHO is urging more effective implementation of available tools and strategies to prevent, diagnose and treat malaria, particularly among marginalized populations.</span><span lang="EN-US"> </span><span style="font-weight: normal;" lang="EN-US">According to the latest World malaria report, published in December 2022, in 2021, nearly half of the worlds population was at risk of malaria. There were an estimated 247 million new cases of malaria and the estimated number of malaria deaths stood at 619 000 and n</span><span style="font-weight: normal;" lang="EN-US">early 80% of malaria deaths in the African Region were among children under the age of five.</span><span style="color: rgb(51, 102, 153);" lang="EN-US"> </span></span><span style="font-size: small;"><span style="font-family: Verdana;"><span style="color: rgb(51, 102, 153);" lang="EN-US"> </span></span></span></p>
<hr />
<p><span style="font-size: small;"><b><span style="color: rgb(0, 102, 0);">The Threat of Antimalarial Drug Resistance in Africa</span></b></span><b><span style="font-size:12.5pt;color:#006600;"> </span></b></p>
<p><span style="font-family: Verdana;"><b><span style="font-weight: normal;">The emergence of multidrug resistance is a public health concern that threatens the sustainability of global efforts to reduce the burden of malaria. WHO recently published, the strategy to respond to antimalarial drug resistance in Africa, aimed at minimizing the threat and impact of antimalarial drug resistance of Plasmodium falciparum parasites in Africa. The efficacy of conventional antimalarial drugs is perennially threatened by drug resistance; therefore, there is an ongoing need for novel drug discovery and development to overcome antimalarial drug resistance. </span></b></span></p>
<hr />
<p><span style="color: rgb(0, 102, 153);"><b><span style="font-size: 12.5pt;">New-generation Antimalarial Drug: The Development of IgY</span></b></span><b style="font-size: medium;"><span style="color: rgb(51, 102, 153);" lang="EN-US">(ΔFc)</span></b><span style="color: rgb(0, 102, 153);"><b><span style="font-size: 12.5pt;"> Antibody to Plasmodium falciparum as a Passive Antibody for Specific Treatment of Severe Malaria Infection, including MDR Malaria </span></b> </span></p>
<div>
<div><span style="font-family: Verdana;">
<p>Plasmodium <i>falciparum</i> malaria is a leading cause of morbidity and mortality in developing countries. The urgent problem of antimalarial drug resistance in Africa continues to be a public health challenge. Despite several approaches to prevent established infection, no single approach offers complete protection, so a multilayered approach is needed. A new source and innovation solutions are eagerly needed to solve this critical global health issue.</p>
</span><span style="font-family: Verdana;">
<p>Good Biotech’s innovative duck IgY(ΔFc) antibody is a commercialized & validated technology with various applications. Duck IgY(ΔFc) antibody, a naturally existing analog to <span style="font-family: Verdana;"><span style="font-size:9.0pt;font-family:
"Verdana",sans-serif;mso-fareast-font-family:新細明體;mso-bidi-font-family:Arial;
color:black;mso-font-kerning:0pt;mso-ansi-language:EN-US;mso-fareast-language:
ZH-TW;mso-bidi-language:AR-SA" lang="EN-US">mammalian IgG (Fab’)<sub>2</sub> antibodies</span>, offers an alternative solution and is expected to be the promising candidate with the breakthrough technology as a new approach for the treatment of severe and multidrug resistance (MDR) Malaria.</span></p>
<p><span style="font-family: Verdana;">Duck IgY(ΔFc) Polyclonal antibody therapy may be described as a multi-target approach, providing polyvalent interactions that permit the applications of therapeutic strategies against multiple epitopes and targets, especially for those emerging antibiotic-resistant microorganisms, such as multi-resistant Tuberculosis (TB) as well as Malaria parasites. The technology enables a quick-response production capability to characterize high titer & high efficacy polyclonal mixture specific targets with fast & mass production to respond to market demand.</span></p>
<hr />
</span></div>
</div>
<div><b><span style="font-size:12.5pt;
font-family:"Calibri",sans-serif;
color:#006600;">Antibody-derived Therapeutics</span></b></div>
<p><span style="font-family: Arial;"><span style="font-size: small;">In 2021, the World Health Organization endorsed a malaria vaccine for use in at-risk children. But the vaccine is only partially effective in preventing severe malaria. Researchers have been pursuing new approaches for the prevention and elimination of malaria. Unlike a vaccine, which requires time to induce protective immunity and depends on the hosts ability to mount an immune response, passive antibody can critically confer protection regardless of the immune status of the hosts. Antibody based therapies could, in therapy, be developed against any existing pathogen (Casadevall A, 2002). Monoclonal antibody to Toxoplasma <i>gondii</i> has reported to interfere with intracellular replication of the parasites (MineoJ.R. et al., 1994). Antibodies to Plasmodium<i> falciparum</i> schizont antigen-1 (PfSEA-1) block parasite egress from RBCs and protect against malaria infection has well discussed (Raj D.K. et al., 2014). Also, the surface antigens (VSA) expressed on the surface of Plasmodium<i> falciparum </i>infected RBC can be a candidate for active immunity (Marsh K. et al,. 1989, Dodoo D. et al,. 2001). In addition, in 1961, a research article claimed that passive transfer of IgG from African malaria immune donors to infected children resulted in a reduced parasitemia (Cohen et al,. 1961).</span></span></p>
<hr />
<div>
<p class="MsoNormal"><span style="font-size: medium;"><span style="font-family: Verdana;"><b><span style="color: rgb(0, 102, 0);" lang="EN-US">New-generation Anti-P. falciparum Antibody derived from Duck IgY(ΔFc) Antibody Immunoglobulins to Combat Malaria Infection</span></b></span></span><b><span style="font-size:13.5pt;font-family:"新細明體",serif;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin;color:#336699;mso-font-kerning:0pt" lang="EN-US"><o:p></o:p></span></b></p>
<p><span style="font-family: Verdana;">The advantages of antibody-based therapies include versatility, low toxicity, pathogen specificity, enhancement of immune function and favorable pharmacokinetics, etc. (Casadevall A, <i>Emerg Infect Dis</i>. 2, 200-8 1996). To date, there are numerous plasmodium parasite proteins as monoclonal antibody targets; however, until now there is no therapeutic antibody available for massive production (only in a small clinical trial). The development of monoclonal antibodies (mAbs) cocktail for effective malaria prevention is rather difficult due to the fact that monoclonal antibodies recognize only a single epitope which means that they have limited usefulness against pathogens that exhibit antigenic variation. Not to mention that the efficacy may not be as expected even for making monoclonal antibodies (Mabs) cocktail for malaria.</span></p>
<p><span style="font-family: Verdana;">Besides, it is known that traditional mammalian IgG-based polyclonal antibodies are not possible to develop polyclonal IgG antibody-based malaria drugs mainly because of the production difficulties and safety issues, such as the side effects of life-threatening allergies.</span></p>
<p><span style="font-family: Verdana;">Thanks to the unique characteristics of duck IgY(ΔFc) antibody, IgY(ΔFc) antibody-derived biotherapeutics, on the other hand, have achieved promising results. Good Biotech has dedicated our R&D projects to areas including antivenoms, antidotes, and neutralizing antibodies, and the targets are for medical emergencies treating new or reemerging pathogens and combating drug-resistant bacterial/ fungal infections of unmet medical needs. Polyclonal antibody preparations have the advantage of consisting of diverse immunoglobulins that target different antigens, the heterogeneity in isotype composition confers broader biological activity through the various constant regions. Polyclonal antibody preparations, in particular duck IgY (ΔFc) antibodies, are generally relatively easy to make, provided that therapeutic antibodies are available.</span></p>
<p><span style="font-family: Verdana;">Duck IgY (ΔFc) polyclonal anti-Plasmodium falciparum antibody is expected to block, to interfere/inhibit Malaria parasite replication as well as has the capability of protection against severe malaria (including MDR malaria) infection. </span></p>
<hr />
</div>
<p><span style="font-size: small;"><span style="font-family: Verdana;"><b><span style="color: rgb(0, 102, 0);">The Advantages for the Use of Duck IgY(ΔFc) derived Therapeutic Antibodies</span></b></span></span></p>
<p><span style="font-family: Verdana;">IgY(ΔFc) antibody-derived biotherapeutics enjoy the advantages including:</span></p>
<p><span style="font-family: Verdana;">• For the Treatment of a Variety of Specific Illnesses, e.g., envenomation, intoxication, and infections caused by pathogens and/or antibiotics-resistant bacterial<br />
• React with Multiple Epitopes on a Single Target<br />
• Antibodies can be raised in a short time when a new infectious disease bursts out.<br />
• Safety, Effective, Low Production Cost, Short Production Process and High Yields<br />
• No bio-hazards Imposed.</span></p>
<p><span style="font-family: Verdana;">It is expected that the development of Anti-P. falciparum Antibody derived from Duck IgY(ΔFc) Antibody Immunoglobulins has great potential to become the novel solution to prevent as well as for the treatment of malaria infection to meet the high unmet medical needs of malaria.</span></p>
<hr />
<div>
<p><span style="font-size: small;"><span style="font-family: Verdana;"><b><span style="color: rgb(0, 102, 0);">Benefits and Global Strategy Alignment of Using Antimalarial IgY(ΔFc) Ab for Prevention as well as for the Treatment of Severe Malaria & Multidrug Resistance Malaria Infection</span></b></span></span></p>
<ul>
<li><span style="font-family: Verdana;"><b style="text-indent: -13.65pt;">Multipotent</b></span></li>
</ul>
<p><span style="font-family: Verdana;"><span style="text-indent: -13.65pt;">The nature of monoclonal antibody which recognizes only a single epitope makes them have limited function in the face of pathogens that</span><span style="text-indent: -13.65pt;">exhibit antigenic variation. Duck polyclonal antibody enjoys the advantages, such as consisting of diverse immune-globulins that target </span><span style="text-indent: -13.65pt;">different antigens; the heterogeneity in isotype composition confers broader biological activity which has the “multipotent” to target several </span><span style="text-indent: -13.65pt;">species with constant regions. Hence, anti-malaria IgY(ΔFc) polyclonal antibody has the potential to become a new generation multi- </span><span style="text-indent: -13.65pt;">targeted Malaria Therapeutics.</span></span></p>
<ul>
<li><span style="font-family: Verdana;"><b style="text-indent: -18pt;">Safe</b></span></li>
</ul>
<p><span style="font-family: Verdana;"><span style="text-indent: -13.65pt;">Duck antibody has no immunological cross-reactivity between avian and mammalian antibodies. They recognize more specific epitopes </span><span style="text-indent: -13.65pt;">avoid non-specific binding and have high purity, free of egg white protein for eradicating side effects such as anaphylaxis.</span></span></p>
<ul>
<li><span style="font-family: Verdana;"><b style="text-indent: -18pt;">Effective</b></span></li>
</ul>
<p><span style="font-family: Verdana;"><span style="text-indent: -13.65pt;">Duck antibody recognizes more specific epitopes, so it can perform high antibody titer response as well as high Malaria antibody titer; </span><span style="text-indent: -13.65pt;">therefore, Antimalarial IgY(ΔFc) Ab performs high malaria efficacy. Consequently, Antimalarial IgY(ΔFc) Ab enables patients to receive </span><span style="text-indent: -13.65pt;">minimum heterogeneous protein, to minimize the risk of early adverse reactions and to prevent serum sickness from severe illness </span><span style="text-indent: -13.65pt;">(reaction), thus render treatment safer and more effective.</span></span></p>
<ul>
<li><span style="font-family: Verdana;"><b style="text-indent: -18pt;">Affordable</b></span></li>
</ul>
<p><span style="font-family: Verdana;"><span style="text-indent: -13.65pt;">Efficient commercial-scale production and cost-effective</span></span></p>
<ul>
<li><span style="font-family: Verdana;"><b style="text-indent: -18pt;">Accessible</b></span></li>
</ul>
<p><span style="font-family: Verdana;"><span style="text-indent: -13.65pt;">Flexible for various administrations (oral administration, spray, injection, lyophilized powder form, and paste). </span><span style="text-indent: 12pt;">High stability, easier for logistics management.</span></span></p>
<hr />
</div>
<div><span style="font-size: smaller;"><span style="font-family: Verdana;"> </span></span><span style="font-size: medium;"><span style="font-family: Arial;">
<div><span style="font-size: small;"><span style="font-family: Arial;"><b style="font-size: smaller; font-family: Verdana;"><span style="font-weight: normal;">Good Biotech is currently seeking a strategic partnership for the project “The Development of IgY(ΔFc) Antibody to Plasmodium falciparum as a Passive Antibody for Specific Treatment of Severe Malaria Infection, including MDR Malaria” with the partner who wish to access our experience and insights, as well as access the following core competencies for this promising project.</span></b></span></span></div>
</span></span>
<div><span style="font-family: Times New Roman;"> </span></div>
<div><span style="font-family: Verdana;"><b><span style="font-weight: normal;">If you are interested in exploring partnering with Good Biotech, please contact our Partnering Team at <span style="color: rgb(68, 114, 196);">partnership@good-biotech.com.</span></span></b></span></div>
</div>
<p> </p>text/html1970-01-01T00:00:00+01:00http://good-biotech.comgood-biotech.comUnique Triplex CRP LIT Assay on Hitachi analyzers
http://good-biotech.com/news/?id=50
<p><img src="/archive/image/Good%20Biotech_Triplex%20CRP%20LIT%20Assay%20on%20Hitahi%201%20page.jpg" alt="" width="725" height="1029" /></p>
<p>Clink <a href="http://www.good-biotech.com/products/index.php?type_id=36&top=0"><span style="color: rgb(128, 128, 0);"><u><b>Triplex CRP LIT Assay</b></u></span></a> for more information and please contact <a href="mailto:partnership@good-biotech.com?subject=Triplex%20CRP%20LIT%20Assay"><span style="color: rgb(0, 0, 255);"><u><b>Business Development</b></u></span> </a>to discuss your collaboration ideas with us.</p>text/html1970-01-01T00:00:00+01:00http://good-biotech.comgood-biotech.comCustom Good Biotech IgY (ΔFc) Depletion Columns
http://good-biotech.com/news/?id=49
<p class="MsoNormal"><span style="color: rgb(51, 102, 153);"><span style="font-size: medium;"><b style="mso-bidi-font-weight:normal"><span style="font-family: Arial;" lang="EN-US">Interested in a custom-made DEPLETION COLUMN? </span></b></span></span></p>
<p><span style="font-size: 10pt; font-family: Arial;" lang="EN-US">Good Biotech provides the custom service for <a href="http://www.good-biotech.com/products/index.php?type_id=17&top=0"><b><span style="color: rgb(0, 0, 255);">Depletion Column</span></b></a>. Different kinds of Depletion Methods are available as well as Sample Loading Volume can be customized to meet your specifications. </span></p>
<table style="" width="645" cellspacing="1" cellpadding="8" border="0">
<tbody>
<tr>
<td nowrap="nowrap" bgcolor="#ffff99">
<p>Product Name</p>
</td>
<td colspan="4" nowrap="nowrap" bgcolor="#ffff99" align="center">
<p> <b><span style="font-size:10.0pt;font-family:
 Arial;mso-fareast-font-family:新細明體;mso-font-kerning:1.0pt;mso-ansi-language:
 EN-US;mso-fareast-language:ZH-TW;mso-bidi-language:AR-SA" lang="EN-US">Good Biotech Human Albumin/IgG/Transferrin 3 in 1 Depletion Columns</span></b></p>
</td>
</tr>
<tr>
<td nowrap="nowrap" bgcolor="#ffff99">
<p>Coulmn Type</p>
</td>
<td bgcolor="#ffff99">
<p> Spin column-S<span style="font-size:9.0pt;font-family:
 Arial;mso-fareast-font-family:新細明體;mso-font-kerning:1.0pt;mso-ansi-language:
 EN-US;mso-fareast-language:ZH-TW;mso-bidi-language:AR-SA" lang="EN-US"><img src="/archive/image/Spin column S.jpg" alt="" width="100" height="100" /></span></p>
</td>
<td bgcolor="#ffff99">
<p> Spin column-L<img src="/archive/image/Spin column L.jpg" alt="" width="100" height="100" /></p>
</td>
<td bgcolor="#ffff99">
<p> Open column<img src="/archive/image/Open column.jpg" alt="" width="100" /></p>
</td>
<td bgcolor="#ffff99">
<p> LC column<img src="/archive/image/LC olumn.jpg" alt="" width="100" height="100" /></p>
</td>
</tr>
<tr>
<td bgcolor="#ffffcc">
<p>Column Size</p>
</td>
<td bgcolor="#ffffcc" align="center">
<p><span style="font-family: Arial;"> 1.5ml</span></p>
</td>
<td bgcolor="#ffffcc" align="center">
<p> 10ml</p>
</td>
<td bgcolor="#ffffcc" align="center">
<p> 10ml</p>
</td>
<td bgcolor="#ffffcc" align="center">
<p> 8ml (C10/10)</p>
</td>
</tr>
<tr>
<td bgcolor="#ffffcc">
<p>Depletion Method</p>
</td>
<td bgcolor="#ffffcc" align="center">
<p> Spin-down</p>
</td>
<td bgcolor="#ffffcc" align="center">
<p> Spin-down</p>
</td>
<td bgcolor="#ffffcc" align="center">
<p> Gravity-flow</p>
</td>
<td nowrap="nowrap" bgcolor="#ffffcc" align="center">
<p>Automatic FPLC/LC</p>
</td>
</tr>
<tr>
<td bgcolor="#ffffcc">
<p>Applicable Bead Bed</p>
</td>
<td bgcolor="#ffffcc" align="center">
<p> 0.32ml</p>
</td>
<td bgcolor="#ffffcc" align="center">
<p> 0.64-1.0ml</p>
</td>
<td bgcolor="#ffffcc" align="center">
<p> 2-4ml</p>
</td>
<td bgcolor="#ffffcc" align="center">
<p> 1-5ml</p>
</td>
</tr>
<tr>
<td bgcolor="#ffffcc">
<div>Sample Loading Volume (can be customized)</div>
</td>
<td bgcolor="#ffffcc" align="center">
<p> 15μl</p>
</td>
<td bgcolor="#ffffcc" align="center">
<p> 30~50μl</p>
</td>
<td bgcolor="#ffffcc" align="center">
<p> 100~200μl</p>
</td>
<td bgcolor="#ffffcc" align="center">
<p> 50~250μl</p>
</td>
</tr>
<tr>
<td bgcolor="#ffffcc">
<p>Cycle for Use</p>
</td>
<td bgcolor="#ffffcc" align="center">
<p> 10 cycles</p>
</td>
<td bgcolor="#ffffcc" align="center">
<p> 10 cycles</p>
</td>
<td bgcolor="#ffffcc" align="center">
<p>more than 200 cycles</p>
</td>
<td bgcolor="#ffffcc" align="center">
<p>more than 200 cycles</p>
</td>
</tr>
<tr>
<td nowrap="nowrap" bgcolor="#ffffcc">
<p>Related Products</p>
</td>
<td bgcolor="#ffffcc" align="center">
<div> <span style="color: rgb(0, 0, 255);">(HD-0301-1.5SC)</span></div>
<div> <span style="color: rgb(0, 0, 255);">(HD-0301-1.5KT)</span></div>
</td>
<td bgcolor="#ffffcc" align="center">
<div> (HD-0301-3.0SC)</div>
<div> (HD-0301-5.0SC)</div>
</td>
<td bgcolor="#ffffcc" align="center">
<p> <span style="color: rgb(0, 0, 255);">(HD-0301-10GFC)</span></p>
</td>
<td bgcolor="#ffffcc" align="center">
<p> (HD-0301-10LC)</p>
</td>
</tr>
</tbody>
</table>
<p> </p>
<hr />
<div><span style="font-size: larger;"><span style="color: rgb(51, 153, 102);"><b>Visit related page:</b></span></span></div>
<div>⇒<a href="http://www.good-biotech.com/products/index.php?type_id=23&top=0">Good Biotech 3 in 1 Depletion Column</a></div>
<div>⇒<a href="http://www.good-biotech.com/products/index.php?type_id=22&top=0">Good Biotech 3 in 1 Depletion Spin Column Kit</a></div>
<div>⇒<a href="http://www.good-biotech.com/products/index.php?type_id=21&top=0">Good Biotech 3 in 1 Depletion Spin Column</a></div>
<div> </div>
<div>
<div> </div>
<p><span style="color: rgb(255, 0, 0);"><b>Why the IgY(ΔFc)-based affinity column is your preferred choice, click Good Biotech IgY (ΔFc) <a href="http://www.good-biotech.com/products/index.php?type_id=17&top=0"><u><span style="color: rgb(0, 102, 51);">Depletion Columns</span></u></a> for more infomation.</b></span></p>
<p><a href="http://www.good-biotech.com/contact_us/"><span style="color: rgb(0, 0, 255);"><i><b><span style="font-size: small;">Contact us</span></b></i></span></a><span style="font-size: small;"> to Customizing your own Depletion Column Today !</span></p>
</div>text/html1970-01-01T00:00:00+01:00http://good-biotech.comgood-biotech.comWhole Blood CRP LIT POCT for Healthcare Professional
http://good-biotech.com/news/?id=48
<p><img src="/archive/image/20220317%20Whole%20Blood%20POCT.jpg" alt="" width="725" height="1028" />.</p>
<p><span style="font-size: small;"><span style="color: rgb(128, 0, 0);"><span style="font-family: Verdana;"><span style="font-size: small;"><span style="color: rgb(51, 102, 255);">Whole Blood CRP LIT Assay-Your Strategic Partner for your POCT development</span></span></span></span></span>; please contact <a href="mailto:partnership@good-biotech.com?subject=Whole%20Blood%20CRP%20POCT%20for%20Professional%20Use"><span style="color: rgb(0, 0, 255);"><u><b>Business Development</b></u></span> </a>to discuss your collaboration ideas with us.</p>text/html1970-01-01T00:00:00+01:00http://good-biotech.comgood-biotech.comDuck IgY(ΔFc) Ab derived Anti-Obesity Nutraceutical
http://good-biotech.com/news/?id=46
<h3><span style="color: rgb(0, 102, 0);">The Urgent Need of Controlling the Global Obesity Epidemic</span></h3>
<h3><img alt="" data-cke-saved-src="/archive/image/obesity.jpg" src="http://www.good-biotech.com/archive/image/obesity.jpg" width="111" hspace="3" height="80" /></h3>
<p><span style="font-size: larger;">According to WHO: Obesity is one of today most blatantly visible – yet most neglected – public health problems. Paradoxically coexisting with undernutrition, an escalating global epidemic of overweight and obesity – 「globesity」 – is taking over many parts of the world. If immediate action is not taken, millions will suffer from an array of serious health disorders.</span></p>
<p><span style="font-size: larger;">The Global Burden of Disease Study and the WHO have recently documented that obesity is indeed a major contributor to ill-health, disability and mortality in many regions of the world. Obesity or accumulation of excessive fat in body can increase the risk of serious health problems, and Obese people are at risk of diseases including Cardiovascular Disease, Coronary Artery Disease, Type 2 Diabetes, Gallbladder Disease, Osteoarthritis, Sleep Apnea, Digestive problems, Reproductive issues.</span></p>
<hr />
<h3><span style="color: rgb(0, 102, 0);">IgY(ΔFc)Antibody derived New Generation Anti-Obesity Nutraceutical</span></h3>
<p><span style="font-size: larger;">The intestinal ecosystem comprises a complex microbial community. The microbial communities living in the human intestine can have profound impact on our well-being and health. In the case of any imbalance in the gut microbiota, they can affect the normal metabolic pathways which lead to immune dysfunctions. Many studies have indicated that intestinal microflora dysbiosis may trigger the onset of diabetes and obesity-related issues, such as cardiovascular disease.</span></p>
<p><span style="font-size: larger;">The development of Oral Administration of duck IgY(ΔFc) antibodies specific to Lipase, Amylase, and gut microbiota including Firmicutes can play a crucial role. These specific anti-obesity IgY(ΔFc) antibodies can effectively reduce the intestinal absorption of lipid and carbohydrate as well as regulate & balance gut microbiota communities and therefore achieve the ultimate goals of body weight control and the prevention of metabolic syndrome.</span></p>
<hr />
<h3><span style="color: rgb(0, 102, 0);">The Competitive Advantages of Duck Egg Yolk IgY (ΔFc) Antibodies derived Oral Administration Healthcare Products</span></h3>
<ul>
<li><span style="font-size: larger;">Safety (no acute and chronic toxicity)
<p> </p>
</span></li>
<li><span style="font-size: larger;">Proved to be effective (with a series of US FDA 510(k) cleared clinical diagnostics products</span></li>
<li><span style="font-size: larger;">Easily accepted by customers as food products & oral-administration Nutraceuticals</span></li>
<li><span style="font-size: larger;">Production can be easily scaled up and commercialized</span></li>
<li><span style="font-size: larger;">Reduce the use of antibiotics</span></li>
<li><span style="font-size: larger;">Suitable for oral administration</span></li>
<li><span style="font-size: larger;">Duck yolk antibody is stable at pH2.5 for 4 hours (~75% activity)</span></li>
</ul>
<hr />
<h3><span style="color: rgb(0, 102, 0);">Benefits of Using High Purified Duck Egg Yolk IgY (ΔFc) Antibodies in Foods for Specific Health Use (FOSHU)</span></h3>
<ul>
<li><span style="font-size: larger;">No excess fats/cholesterol ingested by users</span></li>
<li><span style="font-size: larger;">Eliminate the risk of food allergy</span></li>
<li><span style="font-size: larger;">Be able to quantify the administered specific antibody</span></li>
<li><span style="font-size: larger;">Be able to be processed into various forms of food formulas, e.g.</span></li>
<p><span style="font-size: larger;"> <img src="/archive/image/blue21_next.gif" alt="" width="12" height="12" /> In liquid</span></p>
<p><span style="font-size: larger;"> <img src="/archive/image/blue21_next.gif" alt="" width="12" height="12" /> In lyophilized powder</span></p>
<p><span style="font-size: larger;"> <img src="/archive/image/blue21_next.gif" alt="" width="12" height="12" /> Being easily further processed to oral capsule or tablet</span></p>
</ul>
<hr />
<p><span style="font-size: larger;">Good Biotech is currently seeking a strategic partnership for [IgY(ΔFc) Antibody derived New Generation Anti-Obesity Nutraceutical] with the partner who wish to access our experience and insights, as well as access the following core competencies for this promising project.</span></p>
<p><span style="font-size: larger;">If you are interested in exploring partnering with Good Biotech, please contact our Parting Team at </span><a href="mailto:partnership@good-biotech.com"><span style="font-size: larger;">partnership@good-biotech.com</span></a><span style="font-size: larger;">.</span></p>
<p> </p>text/html1970-01-01T00:00:00+01:00http://good-biotech.comgood-biotech.comDuck IgY(ΔFc) Ab derived Snake Venom POCT Kit
http://good-biotech.com/news/?id=43
<p><img src="/archive/20210827 snake venom POCT kit.png" alt="" /></p>
<p> </p>
<p><img src="/archive/20210827.jpg" alt="" /></p>
<p>Clink <a href="http://www.good-biotech.com/content/index.php?parent_id=13"><span style="color: rgb(0, 102, 0);"><b>Duck IgY(ΔFc) Antibody Snake Venom POCT Kit</b></span></a> for more information.</p>
<p>Contact <a href="mailto:partnership@good-biotech.com"><span style="color: rgb(0, 0, 255);"><u><b>Business Development</b></u></span></a> to discuss your collaboration ideas with us.</p>
<p> </p>text/html1970-01-01T00:00:00+01:00http://good-biotech.comgood-biotech.comTrade Control and Expert System (TRACES) Approval
http://good-biotech.com/news/?id=41
<p><!--[if gte mso 9]><xml>
<w:WordDocument>
<w:View>Normal</w:View>
<w:Zoom>0</w:Zoom>
<w:PunctuationKerning />
<w:DisplayHorizontalDrawingGridEvery>0</w:DisplayHorizontalDrawingGridEvery>
<w:DisplayVerticalDrawingGridEvery>2</w:DisplayVerticalDrawingGridEvery>
<w:ValidateAgainstSchemas />
<w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
<w:IgnoreMixedContent>false</w:IgnoreMixedContent>
<w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
<w:Compatibility>
<w:SpaceForUL />
<w:BalanceSingleByteDoubleByteWidth />
<w:DoNotLeaveBackslashAlone />
<w:ULTrailSpace />
<w:DoNotExpandShiftReturn />
<w:AdjustLineHeightInTable />
<w:BreakWrappedTables />
<w:SnapToGridInCell />
<w:WrapTextWithPunct />
<w:UseAsianBreakRules />
<w:DontGrowAutofit />
<w:UseFELayout />
</w:Compatibility>
<w:BrowserLevel>MicrosoftInternetExplorer4</w:BrowserLevel>
</w:WordDocument>
</xml><![endif]--></p>
<p><!--[if gte mso 9]><xml>
<w:LatentStyles DefLockedState="false" LatentStyleCount="156">
</w:LatentStyles>
</xml><![endif]--><!--[if gte mso 10]>
<style>
/* Style Definitions */
table.MsoNormalTable
{mso-style-name:表格內文;
mso-tstyle-rowband-size:0;
mso-tstyle-colband-size:0;
mso-style-noshow:yes;
mso-style-parent:"";
mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
mso-para-margin:0cm;
mso-para-margin-bottom:.0001pt;
mso-pagination:widow-orphan;
font-size:10.0pt;
font-family:"Times New Roman";
mso-fareast-font-family:"Times New Roman";
mso-ansi-language:#0400;
mso-fareast-language:#0400;
mso-bidi-language:#0400;}
</style>
<![endif]--><!--[if gte mso 9]><xml>
<w:WordDocument>
<w:View>Normal</w:View>
<w:Zoom>0</w:Zoom>
<w:PunctuationKerning />
<w:DisplayHorizontalDrawingGridEvery>0</w:DisplayHorizontalDrawingGridEvery>
<w:DisplayVerticalDrawingGridEvery>2</w:DisplayVerticalDrawingGridEvery>
<w:ValidateAgainstSchemas />
<w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
<w:IgnoreMixedContent>false</w:IgnoreMixedContent>
<w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
<w:Compatibility>
<w:SpaceForUL />
<w:BalanceSingleByteDoubleByteWidth />
<w:DoNotLeaveBackslashAlone />
<w:ULTrailSpace />
<w:DoNotExpandShiftReturn />
<w:AdjustLineHeightInTable />
<w:BreakWrappedTables />
<w:SnapToGridInCell />
<w:WrapTextWithPunct />
<w:UseAsianBreakRules />
<w:DontGrowAutofit />
<w:UseFELayout />
</w:Compatibility>
<w:BrowserLevel>MicrosoftInternetExplorer4</w:BrowserLevel>
</w:WordDocument>
</xml><![endif]--></p>
<p><!--[if gte mso 9]><xml>
<w:LatentStyles DefLockedState="false" LatentStyleCount="156">
</w:LatentStyles>
</xml><![endif]--><!--[if gte mso 10]>
<style>
/* Style Definitions */
table.MsoNormalTable
{mso-style-name:表格內文;
mso-tstyle-rowband-size:0;
mso-tstyle-colband-size:0;
mso-style-noshow:yes;
mso-style-parent:"";
mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
mso-para-margin:0cm;
mso-para-margin-bottom:.0001pt;
mso-pagination:widow-orphan;
font-size:10.0pt;
font-family:"Times New Roman";
mso-fareast-font-family:"Times New Roman";
mso-ansi-language:#0400;
mso-fareast-language:#0400;
mso-bidi-language:#0400;}
</style>
<![endif]--></p>
<p class="MsoNormal" style="mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
text-align:justify;text-justify:inter-ideograph;mso-pagination:widow-orphan"><span style="font-size: small;"><b><span style="color: rgb(51, 102, 153);" lang="EN-US">Trade Control and Expert System (TRACES) Registered Facility</span></b></span><span style="font-size: small;"><span style="font-family: Arial;"><span lang="EN-US"> </span></span></span><!--[if gte mso 9]><xml>
<w:WordDocument>
<w:View>Normal</w:View>
<w:Zoom>0</w:Zoom>
<w:PunctuationKerning />
<w:DisplayHorizontalDrawingGridEvery>0</w:DisplayHorizontalDrawingGridEvery>
<w:DisplayVerticalDrawingGridEvery>2</w:DisplayVerticalDrawingGridEvery>
<w:ValidateAgainstSchemas />
<w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
<w:IgnoreMixedContent>false</w:IgnoreMixedContent>
<w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
<w:Compatibility>
<w:SpaceForUL />
<w:BalanceSingleByteDoubleByteWidth />
<w:DoNotLeaveBackslashAlone />
<w:ULTrailSpace />
<w:DoNotExpandShiftReturn />
<w:AdjustLineHeightInTable />
<w:BreakWrappedTables />
<w:SnapToGridInCell />
<w:WrapTextWithPunct />
<w:UseAsianBreakRules />
<w:DontGrowAutofit />
<w:UseFELayout />
</w:Compatibility>
<w:BrowserLevel>MicrosoftInternetExplorer4</w:BrowserLevel>
</w:WordDocument>
</xml><![endif]--></p>
<p><!--[if gte mso 9]><xml>
<w:LatentStyles DefLockedState="false" LatentStyleCount="156">
</w:LatentStyles>
</xml><![endif]--><!--[if gte mso 10]>
<style>
/* Style Definitions */
table.MsoNormalTable
{mso-style-name:表格內文;
mso-tstyle-rowband-size:0;
mso-tstyle-colband-size:0;
mso-style-noshow:yes;
mso-style-parent:"";
mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
mso-para-margin:0cm;
mso-para-margin-bottom:.0001pt;
mso-pagination:widow-orphan;
font-size:10.0pt;
font-family:"Times New Roman";
mso-fareast-font-family:"Times New Roman";
mso-ansi-language:#0400;
mso-fareast-language:#0400;
mso-bidi-language:#0400;}
</style>
<![endif]--></p>
<p class="MsoNormal" style="mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
mso-pagination:widow-orphan"><!--[if gte mso 9]><xml>
<w:WordDocument>
<w:View>Normal</w:View>
<w:Zoom>0</w:Zoom>
<w:PunctuationKerning />
<w:DisplayHorizontalDrawingGridEvery>0</w:DisplayHorizontalDrawingGridEvery>
<w:DisplayVerticalDrawingGridEvery>2</w:DisplayVerticalDrawingGridEvery>
<w:ValidateAgainstSchemas />
<w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
<w:IgnoreMixedContent>false</w:IgnoreMixedContent>
<w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
<w:Compatibility>
<w:SpaceForUL />
<w:BalanceSingleByteDoubleByteWidth />
<w:DoNotLeaveBackslashAlone />
<w:ULTrailSpace />
<w:DoNotExpandShiftReturn />
<w:AdjustLineHeightInTable />
<w:BreakWrappedTables />
<w:SnapToGridInCell />
<w:WrapTextWithPunct />
<w:UseAsianBreakRules />
<w:DontGrowAutofit />
<w:UseFELayout />
</w:Compatibility>
<w:BrowserLevel>MicrosoftInternetExplorer4</w:BrowserLevel>
</w:WordDocument>
</xml><![endif]--></p>
<p class="MsoNormal" style="mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
mso-pagination:widow-orphan"><!--[if gte mso 9]><xml>
<w:LatentStyles DefLockedState="false" LatentStyleCount="156">
</w:LatentStyles>
</xml><![endif]--><!--[if gte mso 10]>
<style>
/* Style Definitions */
table.MsoNormalTable
{mso-style-name:表格內文;
mso-tstyle-rowband-size:0;
mso-tstyle-colband-size:0;
mso-style-noshow:yes;
mso-style-parent:"";
mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
mso-para-margin:0cm;
mso-para-margin-bottom:.0001pt;
mso-pagination:widow-orphan;
font-size:10.0pt;
font-family:"Times New Roman";
mso-fareast-font-family:"Times New Roman";
mso-ansi-language:#0400;
mso-fareast-language:#0400;
mso-bidi-language:#0400;}
</style>
<![endif]-->
<p class="MsoNormal" style="mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
mso-pagination:widow-orphan"><span style="font-family:Arial;
mso-bidi-font-family:新細明體;mso-font-kerning:0pt;mso-bidi-language:LAO" lang="EN-US">Good Biotech obtained a TRACES code and the facility is TRACES registered. The TRACES is run by the European Commission’s Directorate-General for Health & Consumer Protection ; and is the EU’s electronic Internet related to the trade of animal and animal-origin commodities.</span></p>
</p>
<p> </p>
<p> </p>text/html1970-01-01T00:00:00+01:00http://good-biotech.comgood-biotech.comAnti-Obesity, Caries, Gastrointestinal Healthcare Ab
http://good-biotech.com/news/?id=40
<h1><img alt="" src="/archive/image/obesity.jpg" width="111" hspace="3" height="80" /><img alt="" src="/archive/image/medical-weight-loss-clinic.jpg" width="80" hspace="5" height="80" /><img alt="" src="/archive/image/white-teeth.jpg" width="80" hspace="5" height="80" /><img alt="" src="/archive/image/egg.jpg" width="80" hspace="5" height="80" /></h1>
<h2><span style="color: rgb(0, 51, 102);"><span style="font-size: small;"><span style="font-family: Arial;"><b>IgY(ΔFc) Antibody based Anti-Obesity & Anti-Caries & Gastrointestinal Healthcare Neutralizing Antibodies</b></span></span></span></h2>
<p style="
text-align:justify;text-justify:inter-ideograph;"><span style="font-size:10.0pt;font-family:Arial;">Oral administration of IgY(ΔFc) antibodies derived from hyper-immune duck egg yolks has proved for the treatment of a variety of Gastrointestinal (GI) infections, such as bacterial and viral infections. </span></p>
<p style="
text-align:justify;text-justify:inter-ideograph;"><span style="font-size:10.0pt;font-family:Arial;">The technology of production IgY(ΔFc) antibody derived from hyper-immune duck egg yolk is state of the art technology among the production IgY antibodies. Good Biotech Corp. has received promising and solid results for the development duck IgY(ΔFc) antibody derived oral administration products, including:</span></p>
<p style="
text-align:justify;text-justify:inter-ideograph;"><span style="font-size:10.0pt;font-family:Arial;"> </span></p>
<p class="MsoNormal" style="mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
mso-pagination:widow-orphan"><span style="color: rgb(0, 51, 102);"><span style="font-size: 10pt; font-family: Arial;" lang="EN-US">Functional Health Foods (focus on unmet market needs)</span></span></p>
<ul>
<li><span style="font-size:10.0pt;
 font-family:Arial;mso-font-kerning:0pt" lang="EN-US">Anti-Obesity (weight-control): anti-lipase IgY(ΔFc) antibody & anti-amylase IgY(ΔFc) antibody </span></li>
<li><span style="font-size:10.0pt;
 font-family:Arial;mso-font-kerning:0pt" lang="EN-US">Functional healthcare for prevention and reduction infections GI diseases (e.g., H. pylori, Enterovirus, Rotavirus)</span></li>
</ul>
<p class="MsoNormal" style="mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
mso-pagination:widow-orphan"><span style="color: rgb(0, 51, 102);"><span style="font-size: 10pt; font-family: Arial;" lang="EN-US">Biotherapeutics & New Medical Devices & Dental Hygiene and Oral Care Products</span></span><span style="font-size:10.0pt;font-family:Wingdings;mso-fareast-font-family:Wingdings;
mso-bidi-font-family:Wingdings;mso-font-kerning:0pt" lang="EN-US"><span style="mso-list:
Ignore"><span style="font:7.0pt "Times New Roman""><br />
</span></span></span></p>
<ul>
<li><span style="font-size:10.0pt;
 font-family:Arial;mso-font-kerning:0pt" lang="EN-US">Caries-prophylaxis (anti-S.Mutans IgY (ΔFc) antibody)</span></li>
</ul>
<h2><span style="color: rgb(0, 51, 102);"><span style="font-size: small;"><b><span style="font-family: Arial;"><span style="font-family: Arial;">Safe, Effective, Superior & Oral Administration Available</span></span></b></span></span></h2>
<p style="
text-align:justify;text-justify:inter-ideograph;"><span style="font-size:10.0pt;font-family:Arial;">Eggs are normal dietary components and thus there is practically no risk of toxic side effects of IgY. Egg antibody has been given generally regard as safe (GRAS) status in America. Even though egg allergen is considered frequently, according to the reported studies, the described of the dominant egg allergens are egg white proteins and presumable due to </span><span style="font-size:10.0pt;font-family:Arial;">alpha</span><i><span style="font-size:10.0pt;font-family:Arial;">-</span></i><span style="font-size:10.0pt;font-family:Arial;">Livetin</span><span style="font-size:10.0pt;
font-family:Arial;"> of egg yolk. IgY(ΔFc) antibody derived functional health foods offer a unique solution that providing “high pure” and “high titer” of IgY (ΔFc) antibodies that no residual product of egg white proteins as well as of </span><span style="font-size:10.0pt;font-family:Arial;">alpha</span><i><span style="font-size:10.0pt;
font-family:Arial;">-</span></i><span style="font-size:10.0pt;font-family:Arial;">Livetin.</span></p>
<h2><span style="color: rgb(0, 51, 102);"><span style="font-family: Arial;"><b><span style="font-size: small;">Why Good Biotech’s IgY(ΔFc) Ab based Functional Health Foods & Detal Hygiene and Oral Care Products</span></b></span></span></h2>
<p style="
text-align:justify;text-justify:inter-ideograph;"><span style="font-size:10.0pt;font-family:Arial;">Using antibodies as ingredients in functional food to reduce the disease risk and to prevent disease has already become current trend. The IgY(ΔFc) antibodies offer functional foods or ingredients great future opportunities for designing prophylactic strategies prevent infectious gastro-intestinal disease. Our IgY (ΔFc) Antibodies are flexible for various administrations (Oral administration, spray, injection, and paste). Moreover, IgY (</span><span style="font-size:10.0pt;font-family:Arial;">Δ</span><span style="font-size:10.0pt;font-family:Arial;">Fc) antibody derived functional health foods is cost effective. Most important of all, IgY (</span><span style="font-size:10.0pt;font-family:Arial;">Δ</span><span style="font-size:10.0pt;font-family:Arial;">Fc) antibodies used as functional food are able to quantify the administered specific antibody and which also with superior traceability. This can be demonstrated by our FDA 510(k) approved IgY (</span><span style="font-size:10.0pt;font-family:Arial;">Δ</span><span style="font-size:10.0pt;font-family:Arial;">Fc) antibody based immunodiagnostic kits. </span></p>
<div style="
text-align:justify;text-justify:inter-ideograph;"> </div>
<p style="
text-align:justify;text-justify:inter-ideograph;"><span style="font-size:10.0pt;font-family:Arial;">More information about partnering opportunities of IgY(ΔFc) Antibody based functional health foods & oral health products, please contact: </span><span style="font-size:10.0pt;font-family:新細明體;"><a href="mailto:partnership@good-biotech.com"><span style="font-family:Arial;color:#3366CC">partnership@good-biotech.com</span></a> </span></p>text/html1970-01-01T00:00:00+01:00http://good-biotech.comgood-biotech.comNeutralizing Ab to MDR-bacteria_Nosocomial Infection
http://good-biotech.com/news/?id=39
<p style=" text-align:justify;text-justify:inter-ideograph;"><span style="font-size: small;"><span style="font-family: Arial;"><b><span style="color: rgb(0, 51, 153);">Therapeutic IgY(</span></b><b><span style="color: rgb(0, 51, 153);">ΔFc) Antibodies to MDR-Bacteria</span></b></span></span></p>
<div style=" text-align:justify;text-justify:inter-ideograph;"><span style="font-size: small;"><span style="font-family: Arial;"><b><span style="color: rgb(51, 102, 153);">Nosocomial Infections – The Need for New Gram Negative Drugs</span></b></span></span></div>
<p style=" text-align:justify;text-justify:inter-ideograph;"><span style="font-size:10.0pt;font-family:Arial;">Healthcare associated infections (HCAI) are persistent challenge for hospitals worldwide. A prevalence survey showed an average of 8.7% of hospital patients had HCAI. Patients who receive care in intensive care unit (ICU) are at increased risk for nosocomial infections; the emergence of antimicrobial-resistant pathogens in ICUs has made treating these infections very difficult and in some cases, impossible. Gram-negative bacilli are frequently associated with nosocomial infections in ICU patients. Of particular concern is the nosocomial infection caused by enterobacteria-propducing </span><em><span style="font-size:10.0pt;font-family:Arial;font-style:normal;">Extended</span></em><i><span style="font-size:10.0pt;font-family:Arial">-</span></i><em><span style="font-size:10.0pt;font-family:Arial;font-style:normal;">Spectrum</span></em><span><span style="font-size:10.0pt;font-family:Arial"> Beta<i>-</i>Lactamase (ESBLs). Organisms that possess these enzymes are usually resistant to all currently available antimicrobials.</span></span></p>
<div style=" text-align:justify;text-justify:inter-ideograph;"><span style="font-size: small;"><span style="font-family: Arial;"><b><span style="color: rgb(51, 102, 153);">IgY(</span></b><b><span style="color: rgb(51, 102, 153);">ΔFc) Antibody based Neutralizing Antibodies</span></b></span></span></div>
<p style=" text-align:justify;text-justify:inter-ideograph;"><span style="font-size:10.0pt;font-family:Arial;">To address these threats, a number of different therapeutic strategies can be developed. The development of neutralizing antibodies against gram-negative bacilli (e.g. </span><span><span style="font-size:10.0pt; font-family:Arial">Pseudomonas aeruginosa, E coli) has the high potential to meet significant unmet medical needs. Passive administration with specific polyclonal antibodies or fragments target against disease causing agents has the advantages including: </span></span></p>
<ul type="disc">
<li><span><span style="font-size:10.0pt;font-family:Arial">Offering clinical protection immediately after infection with pathogenic bacteria</span></span></li>
<li><span style="font-size:10.0pt;font-family:Arial">Versatility</span></li>
<li><span style="font-size:10.0pt;font-family:Arial;">Low toxicity</span></li>
<li><span style="font-size:10.0pt;font-family:Arial;">Favorable pharmacokinetic </span></li>
<li><span style="font-size:10.0pt;font-family:Arial;">Time saving for the development </span></li>
</ul>
<p><span style="font-size:10.0pt; font-family:Arial;">As for anti-bacteria therapeutic antibody, polyclonal antibodies are favored than monoclonal antibodies due to polyclonal antibodies providing polyvalent interactions that permit the application of therapeutic strategies against multiple epitopes or targets, which means polyclonal antibodies may target numerous biochemical pathways.</span></p>
<p><span style="font-size:10.0pt; font-family:Arial;">The unique advantages of IgY(</span><span style="font-size:10.0pt;font-family:新細明體;">Δ</span><span style="font-size:10.0pt;font-family:Arial;">Fc) antibody as well as the built cutting edge production technology are expected to be the key source of developing neutralizing antibodies for the treatment of nosocomial infections caused by multi-drug resistant gram-negative organisms (MDR-gram negative bacilli).</span></p>
<p> </p>
<p><span style="font-size:10.0pt; font-family:Arial;"><img alt="" src="http://www.good-biotech.com/archive/media/20150619%20Neutralizing%20Ab%20comparison%20chart.jpeg" width="710" height="544" /> </span></p>
<p style=" text-align:justify;text-justify:inter-ideograph;"> </p>
<p style=" text-align:justify;text-justify:inter-ideograph;"><span style="font-size:10.0pt;font-family:Arial;">More information about partnering opportunities of IgY(ΔFc) Antibody derived Neutralizing Antibodies,</span><span style="font-size:10.0pt; font-family:Arial;"> please contact: <a href="mailto:partnership@good-biotech.com"><span style="color:#3366CC">partnership@good-biotech.com</span></a> </span></p>
<div> </div>
<div> </div>text/html1970-01-01T00:00:00+01:00http://good-biotech.comgood-biotech.comDuck Digoxin Immune Fab for Severe Preeclampsia
http://good-biotech.com/news/?id=36
<p><img src="/archive/image/20230914%20Digoxin%20ppt(1).jpg" width="634" height="449" alt="" /></p>
<p class="MsoNormal"><span lang="EN-US" style="font-size:10.0pt;font-family:"Arial",sans-serif">Digoxin Immune-Fab [(Duck IgY(ΔFc)]: Treatment of Digoxin toxicity and severe preeclampsia. The technology breakthroughs the current production barrier and with the capability to produce millions of vials of anti-Digoxin IgY(ΔFc)-Fab per year. </span></p>
<p class="MsoNormal"><span lang="EN-US" style="font-size:10.0pt;font-family:"Arial",sans-serif">More information about</span><span lang="EN-US"><a href="http://www.good-biotech.com/content/index.php?parent_id=17"><i><span style="font-size:10.0pt;font-family:"Arial",sans-serif;color:#336699"> Digoxin Specific IgY(ΔFc)-Fab</span></i></a></span><span lang="EN-US" style="font-size: 10.0pt;font-family:"Arial",sans-serif">.</span></p>
<p class="MsoNormal"><span lang="EN-US" style="font-size:10.0pt;font-family:"Arial",sans-serif">If you are interested in exploring partnering with us to advance this exciting project</span><span lang="EN-US" style="font-family:"Arial",sans-serif">,</span><span lang="EN-US" style="font-size:10.0pt;font-family:"Arial",sans-serif"> contact us at </span><span lang="EN-US"><a href="mailto:partnership@good-biotech.com"><span style="font-size:10.0pt;font-family:"Arial",sans-serif;color:#3366CC">partnership@good-biotech.com</span></a></span></p>text/html1970-01-01T00:00:00+01:00http://good-biotech.comgood-biotech.comIgY(ΔFc) Ab derived Snake Antivenom Immunoglobulins
http://good-biotech.com/news/?id=34
<p style="text-align: left;" class="MsoNormal"><span style="color: rgb(51, 102, 153);"><span style="font-family: Arial;"><span style="font-size: larger;"><b style="mso-bidi-font-weight:normal"><span lang="EN-US">S</span></b><b style="mso-bidi-font-weight:normal"><span lang="EN-US">nake Antivenom Immunoglobulins</span></b></span></span></span></p>
<p><span style="font-family: Arial;"> </span></p>
<p style="mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
text-align:justify;text-justify:inter-ideograph;mso-pagination:widow-orphan" class="MsoNormal"><span style="font-size: small;"><b><span style="color: rgb(0, 51, 102);"><span style="background-color: rgb(255, 255, 255);"><span lang="EN-US">Global burden of snakebites and the shortage of antivenoms</span></span></span></b></span></p>
<p style="mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
text-align:justify;text-justify:inter-ideograph;mso-pagination:widow-orphan" class="MsoNormal"><span style="font-family: Arial;"><span lang="EN-US">The unavailability of effective snake antivenom immunoglobulins to treat the specific types of snakebite envenoming encountered in various regions of the world has become a critical health issue at global level. There is an urgent need to ensure availability of safe, effective and affordable antivenoms, particularly to those in developing countries, a</span></span><span style="font-family: Arial;"><span lang="EN-US">ccording to World Health Organization (WHO).</span></span><span style="font-size: small;"><span style="font-family: Arial;"> </span></span></p>
<p style="mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
text-align:justify;text-justify:inter-ideograph;mso-pagination:widow-orphan" class="MsoNormal"><span style="color: rgb(0, 51, 102);"><span style="font-size: small;"><b><span lang="EN-US">IgY(</span>Δ<span lang="EN-US">Fc) derived Snake Antivenom Immunoglobulins</span></b></span></span> </p>
<p style="mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
text-align:justify;text-justify:inter-ideograph;mso-pagination:widow-orphan" class="MsoNormal"><span style="font-family: Arial;"><span lang="EN-US">Good Biotech has built the proprietary snake antivenom technology platform (as well as snake venom rapid test kit), which enables to <b style="mso-bidi-font-weight:normal">develop</b><b> and optimize each country’s regional species-specific IgY(ΔFc) antibody derived Snake Antivenom Immunoglobulins</b> for effective management and control. All kinds of antivenoms are available including: </span></span></p>
<p><span style="font-family: Arial;"> </span></p>
<p style="mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
text-align:justify;text-justify:inter-ideograph;mso-pagination:widow-orphan" class="MsoNormal"><span style="color: rgb(0, 51, 102);"><span style="font-family: Arial;"><span lang="EN-US">Highly Monospecific Snake Antivenom:</span></span></span></p>
<p style="mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
text-align:justify;text-justify:inter-ideograph;mso-pagination:widow-orphan" class="MsoNormal"> </p>
<ul>
<li><span style="font-family: Arial;"><span lang="EN-US">Neurotoxic</span><span class="st"><span lang="EN-US"> monospecific </span></span><span lang="EN-US">Snake Antivenom</span></span></li>
<li><span style="font-family: Arial;"><span lang="EN-US">Hemato</span><span class="st"><span lang="EN-US">toxic monospecific </span></span><span lang="EN-US">Snake Antivenom </span></span><span style="font-family: Arial;"> </span></li>
</ul>
<p style="mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
text-align:justify;text-justify:inter-ideograph;mso-pagination:widow-orphan" class="MsoNormal"> </p>
<p style="mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
text-align:justify;text-justify:inter-ideograph;mso-pagination:widow-orphan" class="MsoNormal"><span style="color: rgb(0, 51, 102);"><span style="font-family: Arial;"><span lang="EN-US">High-Efficacy Polyspecific Snake Antivenom</span></span></span></p>
<p style="mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
text-align:justify;text-justify:inter-ideograph;mso-pagination:widow-orphan" class="MsoNormal"> </p>
<ul>
<li><span style="font-family: Arial;"><span lang="EN-US">Neurotoxic</span><span class="st"><span lang="EN-US"> Polyspecific </span></span><span lang="EN-US">Snake Antivenom</span></span></li>
<li><span style="font-family: Arial;"><span lang="EN-US">Hematotoxic</span><span class="st"><span lang="EN-US"> Polyspecific </span></span><span lang="EN-US">Snake Antivenom</span><span class="st"><span lang="EN-US"> </span></span></span></li>
</ul>
<p style="mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
text-align:justify;text-justify:inter-ideograph;mso-pagination:widow-orphan" class="MsoNormal"><span style="font-family: Arial;"><span lang="EN-US">According to the results of the studies made by Taiwan Centers for Disease Control, which show that IgY(ΔFc) antibody derived Snake Antivenom Immunoglobulins are much superior to classical equine based snake antivenoms in terms of the <b style="mso-bidi-font-weight:normal">Safety, Efficacy</b>, <b style="mso-bidi-font-weight:
normal">Productivity</b>, and<b style="mso-bidi-font-weight:normal"> Cost effective</b>. Moreover, this unique technology enables <b style="mso-bidi-font-weight:
normal">Fast/Mass Production</b> as well as offers a solution which meets current animal protection trend.</span></span><span lang="EN-US"> </span></p>
<p style="line-height:14.0pt;mso-line-height-rule:exactly;
mso-layout-grid-align:none;text-autospace:none" class="MsoNormal"> </p>
<hr />
<p style="line-height: 14pt;" class="MsoNormal"><span style="color: rgb(0, 51, 102);"><span style="font-size: small;"><b style="mso-bidi-font-weight:
normal"><span lang="EN-US">The Advantages in Comparison with Classical Equine IgG based Snake Antivenom Immunoglobulin</span></b><b style="mso-bidi-font-weight:
normal"><span lang="EN-US">s</span></b></span></span></p>
<ul>
<li><span style="font-family: Arial;"><b style="mso-bidi-font-weight:normal"><span lang="EN-US">Higher </span></b><b style="mso-bidi-font-weight:normal"><span lang="EN-US">Neutralization Activity</span></b><span lang="EN-US"> (unit/mg): Neutralizing activity is 10-20 times higher. </span></span></li>
<li><span style="font-family: Arial;"><b style="mso-bidi-font-weight:normal"><span lang="EN-US"> Excellent Productivity </span></b><span lang="EN-US">(based on: vials</span><span lang="EN-US">/per Kg body weight of the host animal/ per year): Productivity is</span><span lang="EN-US"> </span><span lang="EN-US">≧</span><span lang="EN-US">100 times. </span></span></li>
<li><span style="font-family: Arial;"><b style="mso-bidi-font-weight:normal"><span lang="EN-US">Rapid Immunological Response (Fast Production)</span></b><span lang="EN-US">: For anti-neurotoxic/ hemorrhagic snake venom, satisfied titer can be collected in 2<sup>nd</sup> week after inducement.</span></span></li>
<li><span style="font-family: Arial;"><b style="mso-bidi-font-weight:normal"><span lang="EN-US">Excellent Immune Response Rate</span></b><span lang="EN-US">: 100% immune response rate can be achieved.</span></span></li>
<li><span style="font-family: Arial;"><b style="mso-bidi-font-weight:normal"><span lang="EN-US">Safety and Efficiency (Highly Specific)</span></b><span lang="EN-US">: Horse IgG is a powerfully immunogen, thus equine derived snake antivenom immunoglobulins suffer from life threatening allergic reactions. While on the contrary, IgY (</span>Δ<span lang="EN-US">Fc) based snake antivenom immunoglobulins, derived from egg yolk, are not considered as an allergen. Due to high neutralizing activity of IgY (</span>Δ<span lang="EN-US">Fc) antibody, when IgY (</span>Δ<span lang="EN-US">Fc) based snake antivenom immunoglobulins is used, the victims receive much lower heterogonous protein compared to when IgG based snake antivenom immunoglobulins is used. IgY (</span>Δ<span lang="EN-US">Fc) based snake antivenom immunoglobulins is safer and can greatly minimizes the risk of serum sickness.</span></span></li>
<li><span style="font-family: Arial;"><b style="mso-bidi-font-weight:normal"><span lang="EN-US">Low Cost (Cost Effective) </span></b><span lang="EN-US">: Reducing</span><span lang="EN-US"> </span>≧<span lang="EN-US">90% production cost.</span></span></li>
<li><span style="font-family: Arial;"><b style="mso-bidi-font-weight:normal"><span lang="EN-US">Simple Downstream Processing</span></b><span lang="EN-US">: no need for laborious blood/plasma collection; no need for F(ab’)<sub>2</sub> fragment processing. High pure & specific IgY(</span>Δ<span lang="EN-US">Fc) antibodies are obtained from egg yolks through the proprietary technology.</span></span></li>
<li><span style="font-family: Arial;"><b style="mso-bidi-font-weight:normal"><span lang="EN-US">Meet the current animal-protection trend: </span></b><span lang="EN-US">Animal protection group are that are becoming more and more influential in developing countries, condemn animal rearing for serum production.<b style="mso-bidi-font-weight:
 normal"> </b>Application of the IgY technology driven by legal regulations in favor of animal protection.</span></span><span lang="EN-US"><b style="mso-bidi-font-weight:normal"> </b></span></li>
</ul>
<p style="line-height:14.0pt;mso-line-height-rule:exactly" class="MsoNormal"><b style="mso-bidi-font-weight:normal"><span lang="EN-US"> </span></b></p>
<hr />
<p style="line-height: 14pt;" class="MsoNormal"><span style="color: rgb(0, 51, 102);"><span style="font-size: small;"><b style="mso-bidi-font-weight:normal"><span lang="EN-US">The Novel IgY(ΔFc) Snake Antivenom Technology Offers Solutions to Significant Unmet Medical Needs</span></b></span></span><b style="mso-bidi-font-weight:normal"><span style="color: navy;" lang="EN-US"> </span></b></p>
<p style="line-height: 14pt; text-align: left;" class="MsoNormal"><span style="font-family: Arial;"><span lang="EN-US">Good Biotech’s IgY(ΔFc) derived Snake Antivenom Immunoglobulins are expected to provide a <b style="mso-bidi-font-weight:
normal">Fast</b>, <b style="mso-bidi-font-weight:normal">Safe, Effective</b>, <b style="mso-bidi-font-weight:normal">Affordable, and Accessible </b>solution in response to global health need of snake antivenom immunoglobulins. </span>The primary advantages of this technology including: </span><span lang="EN-US"> </span></p>
<ul>
<li><span style="font-family: Arial;"><b style="mso-bidi-font-weight:normal"><span lang="EN-US">Manufacturing high quality, efficacy, safety, and low-cost <i style="mso-bidi-font-style:normal">polyspecific</i> snake antivenom immunoglobulins against multiple species in geographic regions.</span></b></span></li>
<li><span style="font-family: Arial;"><b style="mso-bidi-font-weight:normal"><span lang="EN-US"> </span></b><b style="mso-bidi-font-weight:normal"><span lang="EN-US">Manufacturing high quality, efficacy, safety, and low cost <i style="mso-bidi-font-style:normal">monospecific </i>snake antivenom immunoglobulins against local species.</span></b></span></li>
<li><span style="color: rgb(0, 102, 102);"><span style="font-family: Arial;"><a href="http://www.good-biotech.com/news/index.php?id=43"><b><u><span lang="EN-US">One-Step, Visual Snake Venom Rapid Test Kit</span></u></b></a></span></span><span style="font-family: Arial;"><b style="mso-bidi-font-weight:normal"><span lang="EN-US">: </span></b><span lang="EN-US">The kit is the one and only one diagnostic kit in the world for <b style="mso-bidi-font-weight:normal">One-Step Rapid Detection (3-5 minutes)</b> of snake venom for medical emergency use. This new generation Snake Venom Rapid Test Kit is much quicker than current methods (eg. ELISA) and can give victims & healthcare professional information needed to act more precisely and effectively in making life-saving decisions.</span></span></li>
<li><span style="font-family: Arial;"><b style="mso-bidi-font-weight:normal"><span style="color: black;" lang="EN-US">Availability in large scale & batch to batch consistency. </span></b></span></li>
<li><span style="font-family: Arial;"><span style="color: black;" lang="EN-US">The production of <b style="mso-bidi-font-weight:normal">lyophilized powder form of IgY(</b></span><b style="mso-bidi-font-weight:normal"><span style="color: black;">Δ</span><span style="color: black;" lang="EN-US">Fc) antibody </span></b><span style="color: black;" lang="EN-US">is relatively easy. Powder form of antibody drugs will offer an easy solution, such as more convenience for the delivery and more stable for storage especially to those developing countries or tropical area where refrigerators are not available.</span></span></li>
<li><span style="font-family: Arial;"><span style="color: black;" lang="EN-US">Ease of handling and maintenance in large numbers of ducks for immunization with various species venoms.<b style="mso-bidi-font-weight:normal"> </b></span><b style="mso-bidi-font-weight:normal"><span lang="EN-US">The technology is game-changing enabling affordable, fast & mass production of highly specific snake antivenom immunoglobulins and can make life-saving polyspecific/ monospecific antivenom for various geographic areas of the world<span style="color: black;">.</span></span></b></span></li>
</ul>
<p style="line-height:14.0pt;mso-line-height-rule:exactly" class="MsoNormal"> </p>
<p style="line-height:14.0pt;mso-line-height-rule:exactly" class="MsoNormal"><strong style="color: rgb(34, 34, 34);">Partnering with Good Biotech</strong></p>
<p style="mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
text-align:justify;text-justify:inter-ideograph;mso-pagination:widow-orphan" class="MsoNormal"><span style="font-family: Arial;"><b style="mso-bidi-font-weight:normal"><span lang="EN-US">Good Biotech is seeking to collaborate with a leading global pharmaceutical company to further the development of Snake Antivenom Immunoglobulins from bench to bedside.</span></b></span></p>
<p style="mso-pagination:widow-orphan" class="MsoNormal"><span style="font-family: Verdana;"><b><span style="font-weight: normal;">If you are interested in exploring partnering with Good Biotech, please contact our Partnering Team at <span style="color: rgb(68, 114, 196);">partnership@good-biotech.com.</span></span></b></span><span style="font-family: Arial;"><span style="color: rgb(0, 51, 102);" lang="EN-US"> </span><u><span style="color: rgb(0, 51, 102);" lang="EN-US"> </span></u><span lang="EN-US"> </span></span></p>
<p style="mso-pagination:widow-orphan" class="MsoNormal"> </p>
<p><span style="text-align: justify; font-family: Arial;"><span lang="EN-US">Related Information:<span style="color: rgb(0, 102, 102);"> <a href="http://www.good-biotech.com/news/index.php?id=43"><u><span style="color: rgb(0, 102, 102);">IgY(</span></u></a></span></span><a href="http://www.good-biotech.com/news/index.php?id=43"><u><span style="color: rgb(0, 102, 102);">Δ<span lang="EN-US">Fc) Antibody based Snake Venom Rapid Test Kit</span></span></u></a></span><a href="http://www.good-biotech.com/news/index.php?id=43" style="text-align: justify;"><u><span style="color: rgb(0, 102, 102);"> </span></u></a></p>
<p> </p>
<p style="mso-pagination:widow-orphan" class="MsoNormal"><span lang="EN-US"> </span></p>